Abstract
Breast cancer remains a major health problem in the United States and other industrialized nations in spite of recent advances in its detection and treatment. Significant progress has been made through decades of basic research and clinical trials, but many questions remain unanswered. The purpose of this chapter is to summarize current information on the treatment of early breast cancer (i.e., breast cancer in which all clinically apparent disease can be removed surgically). The other topics will be covered as much as they are relevant to therapeutic decision making. The treatment of locally advanced and metastatic breast cancer will be addressed in the next chapter.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Forbes JF (1997) The incidence of breast cancer: the global burden, public health considerations. Semin Oncol 24: S120–S135
Greenlee RT, Hill-Harmon MB, Taylor M, Thun M (2001) Cancer statistics 2001. CA Cancer J Clin 51:15–36
Ang P, Garber JE (2001) Genetic susceptibility for breast cancer-risk assessment and counseling. Semin Oncol 28: 419–433
Willett WC, Stampfer MJ, Colditz GA et al (1987) Moderate alcohol consumption and the risk of breast cancer. N Engl J Med 316:1174–1179
Ambrosone CB, Freudenheim JL, Graham S et al (1996) Cigarette smoking, N-Acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 276:1494–1501
American Joint Committee on Cancer (AJCC) (1997) Cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia
Donegan WL (1997) Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 47:28–51
Rosen PP, Groshen S, Saigo PE et al (1989) Pathological prognostic factors in stage 1 (T1 NO M0) and stage II (T1 N1 M0) breast carcinomas: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 7:1239–1251
Bloom HJG, Richardson WW (1957) Histologic grading and prognosis in breast cancer. Br J Cancer XI:359–377
Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334–2351
Foekens JA, Schmitt M, van Putten WL et al (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648–1658
Braun S, Pantel K, Muller P et al (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533
Piccart MJ, Di Leo A, Hamilton A (2000) HER-2, a “predictive” factor ready to use in the daily management of breast cancer patients? Eur J Cancer 36:1755–1761
Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886
Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 90:1371–1388
Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 352:98–101
Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian Tamoxifen Prevention Study. Lancet 352: 93–97
Ernster VL, Barclay J, Kerlikowske K et al (1996) Incidence of and treatment of ductal carcinoma in situ of the breast. JAMA 275:913–918
Fisher B, Anderson S (1994) Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. World J Surg 18:63–69
Goldschmidt RA, Victor TA (1996) Lobular carcinoma in situ of the breast. Semin Surg Oncol 12:314–320
Fisher B, Anderson S, Redmond CK et al (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456–1461
Veronesi U, Saccozzi R, Del Vecchio M et al (1981) Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 305:6–11
Moore MP, Kinne DW (1997) Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 66:2–6
Albertini JJ, Lyman GH, Cox C et al (1996) Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818–1822
Cox CE, Pendas S, Cox JM et al (1998) Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 227:645–653
Early Breast Cancer Trialists Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer: an overview of randomized trials. N Engl J Med 333:1444–1455
Overgaard M, Hansen PS, Overgaard J et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337:949–955
Ragaz J, Jackson SM, Le N et al (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956–962
Buzdar AU, Hortobagyi G (1998) Update on endocrine therapy for breast cancer. Clin Cancer Res 4:527–534
Early Breast Cancer Trialists Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451–1467
Carcangiu ML (1994) RE: endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Can Inst 86:1251–1252
Assikis VJ, Jordan VC (1997) Risks and benefits of tamoxifen therapy. Oncology (Huntingt) 11:S21–S23
Swedish Breast Cancer Cooperative Group (1996) Randomized trial of 2 versus 5 years of adjuvant tamoxifen in postmenopausal women with early-stage breast cancer. J Natl Can Inst 88:1543–1549
Early Breast Cancer Trialists’ Collaborative Group (2000) Ovarian ablation in early breast cancer: Update. Cochrane Database Syst Rev (3) CD000485
Fisher B, Fisher ER, Redmond C et al (1986) Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 4:929–941
Bonnadonna G, Rossi A, Valagussa P (1985) Adjuvant CMF chemotherapy in operable breast cancer: ten years later. World J Surg 9:707–713
Fisher B, Dignam J, Mamounas E et al (1996) Sequential methotrexate and fluorouracil for the treatment of nodenegative breast cancer patients with estrogen receptor-negative tumors; eight-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate and fluorouracil. J Clin Oncol 14:1982–1992
Early Breast Cancer Trialists Collaborative Group (1998) Polychemotherapy for early breast cancer: and overview of the randomized trials. Lancet 352:930–942
Fisher B, Brown AM, Dimitrov MV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive breast cancer patients with tamoxifen-nonresponsive tumors: results from (NSABP) B-15. J Clin Oncol 8:1483–1496
Bonnadonna G, Zambetti M, Valagussa P (1995) Sequential or alternative doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542–547
Henderson IC, Berry D, Demetri G et al (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (Pts) with node-positive primary breast cancer (BC) (abstract no. 390A). Proc Am Soc Clin Oncol 17:101A
Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493
Rodenhuis S, Richel DJ, van der Wall E et al (1998) Randomized trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515–521
Peters WP, Ross M, Vredenburgh JJ et al (1993) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132–1143
Hortobagyi G, Buzdar AU, Theriault RL et al (2000) Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92:225–233
Baynes RD, Dansey RD, Klein JL et al (2001) High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? Semin Oncol 28:377–388
Breast Cancer Surveillance Expert Panel (1997) Recommended breast cancer surveillance guidelines. J Clin Oncol 15:2149–2156
Nathanson KN, Wooster R, Weber BL (2001) Breast cancer genetics: what we know and what we need. Nat Med 7:552–556
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Dragovich, T., Olopade, O. (2003). Early Breast Cancer. In: Vokes, E.E., Golomb, H.M. (eds) Oncologic Therapies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55780-4_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-55780-4_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62818-4
Online ISBN: 978-3-642-55780-4
eBook Packages: Springer Book Archive